Zacks: Analysts Anticipate ZIOPHARM Oncology Inc. (ZIOP) Will Announce Earnings of -$0.11 Per Share

Brokerages forecast that ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) will post earnings per share (EPS) of ($0.11) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for ZIOPHARM Oncology’s earnings, with the lowest EPS estimate coming in at ($0.14) and the highest estimate coming in at ($0.08). ZIOPHARM Oncology posted earnings of ($0.13) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 15.4%. The firm is expected to report its next earnings results on Thursday, March 7th.

On average, analysts expect that ZIOPHARM Oncology will report full year earnings of ($0.51) per share for the current fiscal year, with EPS estimates ranging from ($0.54) to ($0.49). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.32) per share, with EPS estimates ranging from ($0.36) to ($0.26). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for ZIOPHARM Oncology.

ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its earnings results on Friday, November 9th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02).

A number of equities research analysts have issued reports on the company. BidaskClub cut ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, December 22nd. Zacks Investment Research cut ZIOPHARM Oncology from a “buy” rating to a “hold” rating in a research report on Thursday, December 20th. Raymond James raised ZIOPHARM Oncology from a “market perform” rating to an “outperform” rating and set a $5.00 target price for the company in a research report on Thursday, November 15th. Finally, HC Wainwright set a $6.00 target price on ZIOPHARM Oncology and gave the stock a “buy” rating in a research report on Tuesday, November 13th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. ZIOPHARM Oncology currently has an average rating of “Hold” and an average price target of $4.92.

Institutional investors and hedge funds have recently bought and sold shares of the company. Marshall Wace LLP bought a new stake in shares of ZIOPHARM Oncology in the third quarter valued at approximately $115,000. Jane Street Group LLC bought a new stake in shares of ZIOPHARM Oncology in the third quarter valued at approximately $161,000. Raymond James & Associates boosted its position in shares of ZIOPHARM Oncology by 168.3% in the second quarter. Raymond James & Associates now owns 58,290 shares of the biotechnology company’s stock valued at $176,000 after acquiring an additional 36,568 shares during the period. MetLife Investment Advisors LLC boosted its position in shares of ZIOPHARM Oncology by 77.1% in the second quarter. MetLife Investment Advisors LLC now owns 65,990 shares of the biotechnology company’s stock valued at $199,000 after acquiring an additional 28,734 shares during the period. Finally, Belpointe Asset Management LLC bought a new stake in shares of ZIOPHARM Oncology in the third quarter valued at approximately $262,000. 40.07% of the stock is owned by institutional investors.

Shares of ZIOPHARM Oncology stock opened at $2.33 on Tuesday. The company has a market cap of $318.93 million, a price-to-earnings ratio of -4.40 and a beta of 2.39. ZIOPHARM Oncology has a 12-month low of $1.56 and a 12-month high of $5.24.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.

Featured Story: Mutual Funds

Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply